This brief discusses how life sciences companies can adapt portfolio strategy amid rising R&D costs, scientific uncertainty, and evolving payer expectations. It emphasizes integrating evidence generation earlier in development to guide asset prioritization, indication sequencing, and investment decisions. IQVIA highlights the role of real-world evidence, predictive analytics, and scenario modeling in reducing risk and improving capital allocation. The brief underscores that successful portfolios balance innovation with demonstrable value, aligning clinical, regulatory, and commercial evidence to support sustainable growth.

Join for free to read